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Drug-induced hypersensitivity syndrome (DIHS), also 
known as drug reaction with eosinophilia and systemic 
symptoms (DRESS), is a rare and severe skin disease as-
sociated with systemic findings, such as fever, eosinophi-
lia, lymphadenopathy, and internal organ involvement 
that typically develops 2 to 6 weeks after the drug intake, 
following a prolonged course with frequent flare-ups and 
relapses over weeks or even months after discontinuing 
the drug. This syndrome has been reported to be associa-
ted with the intake of anticonvulsants, sulfonamides and 
allopurinol (1). Several mechanisms are involved in its 
pathophysiology, such as drug toxicity, immunological 
imbalance and reactivation of the herpes virus family 
members. Recently, a certain type of human leucocyte 
antigen (HLA) was identified as a predisposing factor 
in DIHS/DRESS. Here, we describe a case of DIHS/
DRESS with remarkable eosinophilic pneumonia caused 
by zonisamide.
CaSE REpoRT
A 46-year-old woman was referred to our hospital with a spiking 
fever, dry cough and skin rash. She had a past medical history 
of subarachnoid haemorrhage due to hereditary haemorrha-
gic telangiectasia (HHT) and had commenced zonisamide 8 
months before. She had been administered with zonisamide for 
2 months, and followed by a washout period of 4 months. On 
the 41st day of the second course of treatment, she developed 
fever with chills, dry cough, and progressive non-pruritic ma-
culopapular eruption with mucosal involvement (Fig. 1 a, b). 
She was hospitalised for further evaluation. Blood tests 
revealed white blood cell count 8,800/mm3 (11% eosinophils, 
49% neutrophils and 27% lymphocytes) and platelet count 
227,000/mm3. Liver function test results were elevated: asparate 
aminotransferase (AST) 67 U/l, alanine aminotransferase (ALT) 
133 U/l; alkaline phosphatase (ALP) 220 U/l. Serologic tests 
for viral infections, including hepatitis B, hepatitis C, Epstein-
Barr virus (EBV), cytomegalovirus, and human herpes virus 
6 (HHV6) were negative. A chest radiograph did not reveal 
a pulmonary infiltration. A skin biopsy of the erythematous 
eruption on her abdomen exhibited spongiosis and vacuolar 
degeneration of epidermal basal keratinocytes. Lymphocytic 
perivascular infiltration was present in the dermis (Fig. 1 c, d). 
Immunohistochemical staining showed that lymphocytes were 
CD8+ lymphocytes with sparse Foxp3 positive lymphocytes in 
the upper dermis (Fig. 1 e, f).
Based upon the patient’s clinical, laboratory, and patholo-
gical findings, DIHS/DRESS was suspected. Zonisamide was 
discontinued immediately and topical steroids were initiated. 
on the 11th day of hospitalisation, however, her dry cough was 
exacerbated. Laboratory tests revealed leucocytosis (11,800/μl) 
with eosinophilia (3,800/μl) and atypical lymphocytosis. HHV6 
IgG titre was increased from × 20 (at day 4) to × 120 (at day 17), 
confirming a reactivation of HHV6. Drug-induced lym phocyte 
stimulation test (DLST) for zonisamide was positive (a stimu-
lation index of 338.2 %). Chest computed tomography (CT) 
showed multiple bilateral nodular lesions with surrounding 
ground-glass-opacity halo (Fig. 1g). Eosinophilic pneumonia 
(Ep) due to zonisamide was suspected and systemic steroid 
therapy (0.5 mg/kg/day of prednisolone) was commenced. 
peripheral eosinophils decreased and her pulmonary lesions 
improved after one week. Oral prednisolone was tapered and 
she was discharged on the 35th day of hospitalisation.
DISCUSSIOn
The diagnosis of DIHS/DRESS is based upon clinical 
and laboratory findings. The European Registry of Severe 
Cutaneous adverse Reaction (RegiSCaR) study group 
has devised a scoring system (2). our case was scored 
as “7” which is classified as a “definite” case (Table SI1). 
Although, bronchoscopy was not successfully performed 
due to cardiopulmonary arrest during the procedure, the 
findings of high eosinophil counts and pneumonia deve-
loping 2 weeks after the onset of DRESS, along with the 
dramatic clinical response to glucocorticoids, strongly 
suggest that EP was a part of DRESS/DIHS rather than a 
separate adverse effect of zonisamide. Although pulmo-
nary involvement is rarely reported, it may lead to life 
threatening adult respiratory distress syndrome (3, 4).
 The pathogenesis of DIHS/DRESS remains uncla-
rified, but reactivation of the herpes virus family has 
been reported at the onset of DIHS/DRESS (5). Tumour 
necrosis factor alpha (TnF-α) and interferon gamma 
(IFn-γ) secreted by the anti-EBV CD8+ T lymphocytes 
in cutaneous and visceral lesions may contribute to the 
development of DIHS/DRESS at the early stage (6). 
one study has demonstrated a switch in the predomi-
nant drug-specific proliferating T-cell population in 
the course of DIHS/DRESS; CD8+ lymphocytes were 
predominant initially, whereas CD4+ lymphocytes 
and regulatory T (Treg) cells (CD4+CD25+Foxp3+) 
proliferated at the recovery stage (7). In our case, im-
munohistochemical staining showed abundant CD8+ 
lymphocytes and few Treg cells infiltration in the upper 
dermis, reflecting the acute phase of DIHS/DRESS. 
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 at present, we do not have clear evidence how Ep 
was induced by zonisamide in DRESS/DIHS. pulmo-
nary involvement in DIHS/DRESS is known to be 
induced by a certain drug (3, 4). We consider that pul-
monary involvement in DIHS/DRESS is not related to 
specific drugs only but may be related to the patient’s 
underlying condition, such as HHT. antigen-presenting 
cells (e.g. alveolar macrophages) are known to ingest 
drugs and present them to T helper cells to release 
interleukin-5, resulting in eosinophil proliferation (8). 
Therefore, in patients with HHT, blood vessels tend to 
be fragile and prone to bleeding (9), which may cause 
the accumulation of zonisamide into the lung and stimu-
late macro phages to initiate the immunologic cascade. 
Clinicians should be aware of the 
possible involvement of the lung in 
the course of DIHS/DRESS. 
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Fig. 1. Clinical appearances. The patient developed a 
maculopapular rash on trunk (a) and face with mucosal 
involvement (b). Histological findings. A skin biopsy 
of the erythematous rash on her abdomen revealed 
spongiosis and vacuolar degeneration of epidermal basal 
keratinocytes. Lymphocytic perivascular infiltration 
was present in the dermis (H&E stain: c and d). 
Immunohistochemical staining showed that lymphocytes 
were positive for CD8 (e) with sparse Foxp3+ 
lymphocytes (f, yellow arrows) in the upper dermis. Bars: 
(c) 300, (d) 50, and (e, f) 100 mm. Chest CT showed 
multiple bilateral nodular lesions with surrounding 
ground-glass-opacity halo at day 16 (orange arrows) (g).
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Table SI. The RegiSCAR scoring system (modified) 
Score –1 0 1 2 Our case
Fever ≥38.5°C No/U Yes 0
Enlarged lymph nodes No/U Yes 0
Eosinophils No/U 0.7–1.499 × 109l–1 ≥ 1.5× 109l–1 1
Atypical lymphocytes No/U Yes 1
Skin involvement 2
Skin rash extent (% body surface area) No/U > 50%
Skin rash suggesting DRESS No/U Yes
Biopsy suggesting DRESS No Yes/U
Organ involvementa 2
Liver No/U Yes Yes
Kidney No/U Yes No/U
Lung No/U Yes Yes
Muscle/heart No/U Yes No/U
Pancreas No/U Yes No/U
Other organ No/U Yes No/U
Resolution ≥15 days No/U Yes 0





If non positive and ≥ 3 of above negative Yes 1
Total score 7
aAfter exclusion of other explanations: 1: one organ; 2: 2 or more organs. Final score: < 2; no case; 2–3: possible case; 4–5; 
probable case >5: definite case.
U: unknown/unclassifiable; HAV: hepatitis A virus; HBV hepatitis B virus; HCV: hepatitis C virus.
According to the RegiSCAR scoring system, our case scored “7”, which is classified as a “definite” case.
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